Loviride

Loviride
Clinical data
Other names	R089439; loveride[citation needed]
ATC code	None;
Identifiers
	IUPAC name 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide;
CAS Number	147362-57-0 ;
PubChem CID	3963;
ChemSpider	3826 ;
UNII	3S1R1LZ09H;
KEGG	D04786 ;
ChEMBL	ChEMBL37624 ;
CompTox Dashboard (EPA)	DTXSID60869958 ;
Chemical and physical data
Formula	C17H16Cl2N2O2
Molar mass	351.23 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N;
	InChI InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) ; Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.^[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR^[2] and AVANTI^[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.

References

^ "Loviride". aidsmap.com. Archived from the original on 2007-09-27.
^ Kroon ED, Wit FW, et al. (CAESAR Coordinating Committee) (1997). "Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial". The Lancet. 349 (9063): 1413–1421. doi:10.1016/S0140-6736(97)04441-3. S2CID 20008082.
^ Gatell J, Lange J, Gartland M (1999). "AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group". Antiviral Therapy. 4 (2): 79–86. doi:10.1177/135965359900400204. PMID 10682152. S2CID 22443598.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] "Loviride". aidsmap.com. Archived from the original on 2007-09-27.

[2] Kroon ED, Wit FW, et al. (CAESAR Coordinating Committee) (1997). "Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial". The Lancet. 349 (9063): 1413–1421. doi:10.1016/S0140-6736(97)04441-3. S2CID 20008082.

[3] Gatell J, Lange J, Gartland M (1999). "AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group". Antiviral Therapy. 4 (2): 79–86. doi:10.1177/135965359900400204. PMID 10682152. S2CID 22443598.

[1]

[2]

[3]

Clinical data

Other names	R089439; loveride^{[citation needed]}
ATC code	None
Identifiers
IUPAC name 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
CAS Number	147362-57-0^N
PubChem CID	3963
ChemSpider	3826^Y
UNII	3S1R1LZ09H
KEGG	D04786^Y
ChEMBL	ChEMBL37624^Y
CompTox Dashboard (EPA)	DTXSID60869958
Chemical and physical data
Formula	C₁₇H₁₆Cl₂N₂O₂
Molar mass	351.23 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N
InChI InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23)^Y Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)